Sahlgrenska University Hospital-Vastra Gotalandsregionen

The Sahlgrenska Medical Center is at the forefront of ophthalmology research, particularly in the treatment of neovascular (wet) age-related macular degeneration (AMD). The center's ongoing studies, such as the SAHLVE Study, focus on comparing the efficacy of different anti-VEGF therapies like bevacizumab and aflibercept. This research aims to determine the optimal treatment regimen by evaluating the number of injections required over a two-year period.

• Neovascular Age-related Macular Degeneration
• Anti-VEGF Therapy
• Intravitreal Injections

Through these studies, the center contributes significantly to improving therapeutic strategies and patient outcomes in the field of ophthalmology.

The Sahlgrenska Medical Center is also a leader in neurology, with a strong focus on Alzheimer's Disease and related cognitive impairments. The center is conducting pivotal research on the safety and efficacy of BIIB080, a promising treatment for mild cognitive impairment due to Alzheimer's Disease. These studies aim to assess changes in clinical dementia ratings and the overall safety of the treatment when administered into the cerebrospinal fluid.

• Alzheimer's Disease
• Mild Cognitive Impairment
• Clinical Dementia Rating

By advancing understanding and treatment options for Alzheimer's Disease, the center plays a crucial role in enhancing the quality of life for affected individuals.